Scinai Immunotherapeutics Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SCNI Nasdaq 2830 www.scinai.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scinai Immunotherapeutics Ltd.

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - Jun 12th, 2025 6:00 am
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Jun 5th, 2025 7:00 am
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - May 30th, 2025 5:00 am
Scinai Announces Annual Financial Results for 2024 - May 7th, 2025 2:01 pm
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases - May 1st, 2025 5:00 am
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions - Mar 27th, 2025 7:25 am
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 - Mar 17th, 2025 5:00 am
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT - Mar 5th, 2025 5:30 am
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences - Jan 6th, 2025 5:30 am
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. - Dec 16th, 2024 7:25 am
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board - Dec 5th, 2024 6:25 am
There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability - Nov 29th, 2024 4:04 am
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board - Nov 27th, 2024 6:00 am
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million - Nov 22nd, 2024 5:15 am
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024 - Oct 31st, 2024 4:59 am
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies - Sep 16th, 2024 5:00 am
Scinai Regains Full Compliance with Nasdaq Listing Requirements - Aug 29th, 2024 4:30 am
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 - Aug 21st, 2024 6:45 am
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder - Aug 20th, 2024 7:30 am
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 - Aug 15th, 2024 5:00 am